NETMINDERS: Netosis in Determination of Respiratory Infection Severity

Sponsor
Assistance Publique - Hôpitaux de Paris (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04318691
Collaborator
(none)
80
1
8
10

Study Details

Study Description

Brief Summary

The study aims to evaluate the prognostic value of alveolar and blood NETosis in patients under mechanical ventilation and treated for an acute low-respiratory tract infection. The main outcome is the occurrence of an acute respiratory distress syndrome (ARDS) according to the Berlin definition.

Condition or Disease Intervention/Treatment Phase
  • Biological: Blood sampling
  • Procedure: Bronchoalveolar lavage

Detailed Description

Neutrophils are the first line of defense against infectious injury. Among the numerous mechanisms involving the immune system, neutrophil extracellular traps (NETs) have been recently described as an additional way neutrophils are able to use to fight against bacteria. NETs are made of DNA and antimicrobial proteins. In the other hand, NETs promote coagulation and may contribute to evolution of severe pneumonia into acute respiratory distress syndrome.

The secondary objectives of the study include the research of the relation between blood

NETosis and alveolar NETosis with:
  • the documentation of invasive pulmonary infection based on microbiological analysis criteria (which would be bacteria or viral) of LBA at admission to ICU;

  • the diagnosis value of usually used biomarkers: procalcitonin and C-reactive protein;

  • marbrure score at admission to ICU;

  • arterial lactatemia;

  • scores of gravity at admission IGSII and SOFA;

  • all-cause mortality at day-28;

  • duration of mechanical ventilation at day-28;

  • duration of amines at day-28;

  • developement of hemodynamic failure;

  • developement of pulmonary circulatory failure.

The study will include 1) 60 patients under mechanical ventilation admitted to the intensive care unit for acute respiratory failure, 2) 10 control patients admitted to the ICU after a planned vascular surgery and 3) 10 healthy subjects.

Study Design

Study Type:
Observational
Anticipated Enrollment :
80 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Netosis in Mechanically Ventilated ICU Patients in Determination of Respiratory Infection Severity
Anticipated Study Start Date :
Apr 1, 2022
Anticipated Primary Completion Date :
Nov 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
acute respiratory failure group

60 patients under mechanical ventilation admitted to the intensive care unit for acute respiratory failure

Biological: Blood sampling
Blood sampling at baseline and at day-3 (10 ml, EDTA tube), test of NETs.

Procedure: Bronchoalveolar lavage
Bronchoalveolar lavage at admission to the ICU with analysis of cytological, bacteriological, viral and anatomopathological, and test of NETs.

vascular surgery control group

10 control patients admitted to the ICU after a planned vascular surgery

Biological: Blood sampling
Blood sampling at baseline and at day-3 (10 ml, EDTA tube), test of NETs.

Healthy volunteers group

10 healthy subjects.

Biological: Blood sampling
Blood sampling at baseline and at day-3 (10 ml, EDTA tube), test of NETs.

Outcome Measures

Primary Outcome Measures

  1. Acute respiratory distress syndrome occurrence [at day-7]

    Acute respiratory distress syndrome occurrence according to the Berlin definition within the first 7 days after ICU admission

Secondary Outcome Measures

  1. Mortality [At day-28]

    Vital statue of patient

  2. Duration of mechanical ventilation [At day-28]

    Duration of mechanical ventilation: number of days without mechanical ventilation.

  3. IGSII score [At admission to ICU]

    IGSII score

  4. SOFA score [At admission to ICU]

    SOFA score

  5. Hemodynamic failure [At day-28]

    Development of a hemodynamic failure

  6. Pulmonary circulation failure [At day-28]

    Development of a pulmonary circulation failure (acute pulmonary heart disease, right ventricle failure)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion criteria:
A/ For all subjets:
  • Be >/= 18 years of age on day of signing informed consent;

  • Affiliated to the french social security - welfare system in France.

B/ Inclusion criteria for acute respiratory failure patients:

admitted to the ICU for acute respiratory failure requiring mechanical ventilation within the first 24 hours after admission and suspected to suffer from an infectious pneumonia, according to the following criteria:

  • recent fever;

  • acute respiratory failure signs (dyspnea, polypnea > 30 cycles/min, hypoxemia PaO2<65 mmHg);

  • pulmonary focal signs of auscultation;

  • evocative signs in chest radiography or chest TDM.

C/ Inclusion criteria for control patients:
  • admitted to the ICU for post-operative management of vascular surgery.
Exclusion Criteria:
A/ For all subjets:
  • pregnancy,

  • nosocomial pneumonia,

  • no social health insurance,

  • neutropenia of any cause;

  • patient refusal.

B/ Exclusion criteria for acute respiratory failure patients:
  • no mechanical ventilation within the first 24 hours after admission to the ICU.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Service de médecine intensive réanimation, Hôpital Ambroise Paré, APHP Boulogne-Billancourt France 92100

Sponsors and Collaborators

  • Assistance Publique - Hôpitaux de Paris

Investigators

  • Principal Investigator: Edouard JULLIEN, MD, Service de médecine intensive réanimation, Hôpital Ambroise Paré, APHP
  • Study Director: Guillaume Geri, MD, PhD, Service de médecine intensive réanimation, Hôpital Ambroise Paré, APHP

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
NCT04318691
Other Study ID Numbers:
  • 2020-A00217-32
First Posted:
Mar 24, 2020
Last Update Posted:
Apr 21, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Assistance Publique - Hôpitaux de Paris
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 21, 2022